Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
Authors' conclusion
We did not find GLP-1RA to be significantly associated with recurrent/progressive DTC. Eligible patients with DTC should not be denied the cardiometabolic benefits of GLP-1RA when clinically indicated.
Study context
- Population
- Patients with DTC at a tertiary care center in New York; median age 49, 71% females, 54% with diabetes mellitus (DM), mean body mass index (BMI) 35 ± 7 kg/m², 84% AJCC stage I, 58% American Thyroid Association (ATA) intermediate or high riskmatched cohort
- Participants
- 1,072 patients
- Exposure
- GLP-1RA exposure vs never exposed
- GLP-1RAn = 536
- Never exposedn = 536reference
- Outcome
- Recurrence or progression of disease
Methodological detailssingle-centre (tertiary care center, New York), matched 1:1 by age, date of DTC diagnosis, TNM stage, BMI and DM, multistate model with GLP-1RA as time-dependent variable, Median GLP-1RA exposure 16 months
- Single-centre (tertiary care center, New York)
- Matched 1:1 by age, date of DTC diagnosis, TNM stage, BMI and DM
- Multistate model with GLP-1RA as time-dependent variable
- Median GLP-1RA exposure 16 months
Main finding
As reported in the abstract
GLP-1RA vs Never exposedHazard ratio (95% CI)P value
Survival cohort; multivariable model adjusted for age, ATA risk, RAI therapy and DM
0.87(0.62–1.21)
P = 0.39Entire cohort; multivariable model adjusted for age, ATA risk, RAI therapy and DM
0.75(0.54–1.03)
P = 0.07Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer. J Clin Endocrinol Metab. Published 15 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →